The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study
Abstract
Objective: Interleukin‐15 (IL‐15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in rheumatoid arthritis (RA) inflammatory synovitis. Our objective was to study the ability of HuMax‐IL15, a human IgG1 anti–IL‐15 monoclonal antibody, to neutralize exogenous and endogenous IL‐15 activity in vitro and to perform a phase I–II dose‐escalation trial with HuMax‐IL15 in patients with active RA. Methods: Mononuclear cells from blood and synovial fluid (SF) of RA patients were isolated and cultured in vitro under experimental conditions involving the addition of HuMax‐IL15. HuMax‐IL15 was administered to 30 RA patients who received no other disease‐modifying antirheumatic drugs in a 12‐week, dose‐ascending, placebo‐controlled, double‐blind, phase I–II proof‐of‐concept study. Results: In vitro studies showed that HuMax‐IL15 suppressed proliferation and induced apoptosis in an IL‐15–dependent cell line, BDB2, and was capable of suppressing the release of interferon‐γ by synovial fluid mononuclear cell (SFMC) cultures induced by exogenous IL‐15. Furthermore, HuMax‐IL15 F(ab′)2 fragments suppressed exogenous IL‐15–induced CD69 expression in RA peripheral blood mononuclear cells and SFMCs, which indicates that HuMax‐IL15 can specifically neutralize several biologic effects of IL‐15 in synovial tissue in vitro. In a phase I–II clinical trial, HuMax‐IL15 was well tolerated clinically, with no significant effects on T lymphocyte subset and natural killer cell numbers. Substantial improvements in disease activity were observed according to the American College of Rheumatology criteria for 20% improvement (63% of patients), 50% improvement (38%), and 70% improvement (25%). Conclusion: These clinical data suggest for the first time that IL‐15 could represent a novel therapeutic target in RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice
Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.771 · Cited by 1,634
Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 Receptor
Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., et al. (1994) · Science · doi:10.1126/science.8178155 · Cited by 1,422
IL-15 Receptor Maintains Lymphoid Homeostasis by Supporting Lymphocyte Homing and Proliferation
Lodolce, J. P., Boone, D. L., Chai, S., Swain, R. E., Dassopoulos, T., Trettin, S., & Ma, A. (1998) · Immunity · doi:10.1016/s1074-7613(00)80664-0 · Cited by 1,299
Potent and Selective Stimulation of Memory-Phenotype CD8+ T Cells In Vivo by IL-15
Zhang, X., Sun, S., Hwang, I., Tough, D. F., & Sprent, J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80564-6 · Cited by 1,245
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells
Dubois, S., Mariner, J., Waldmann, T. A., & Tagaya, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00429-6 · Cited by 913
Cited by
Cytokines in the pathogenesis of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2094 · Cited by 2,529
Self-citationThe Role of Inflammatory and Anti-Inflammatory Cytokines in the Pathogenesis of Osteoarthritis
Wojdasiewicz, P., Poniatowski, Ł. A., & Szukiewicz, D. (2014) · Mediators of Inflammation · doi:10.1155/2014/561459 · Cited by 1,608
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178
Evidence that cytokines play a role in rheumatoid arthritis
Brennan, F. M., & McInnes, I. B. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36389 · Cited by 1,103
Self-citationNew therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Neutrophil function in inflammation and inflammatory diseases
Wright, H. L., Moots, R. J., Bucknall, R. C., & Edwards, S. W. (2010) · Rheumatology · doi:10.1093/rheumatology/keq045 · Cited by 761
Celiac disease: Prevalence, diagnosis, pathogenesis and treatment
Gujral, N. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i42.6036 · Cited by 690
Celiac Disease: From Pathogenesis to Novel Therapies
Schuppan, D., Junker, Y., & Barisani, D. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.008 · Cited by 606
Cytokines in rheumatoid arthritis — shaping the immunological landscape
McInnes, I. B., Buckley, C. D., & Isaacs, J. D. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.171 · Cited by 504
Self-citationFridman, J. S., Scherle, P. A., Collins, R., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B., Collier, P., Favata, M. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902819 · Cited by 463
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
Taylor, P. C., & Feldmann, M. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.181 · Cited by 389
Presentation and Long-Term Follow-up of Refractory Celiac Disease: Comparison of Type I With Type II
Malamut, G., Afchain, P., Verkarre, V., Lecomte, T., Amiot, A., Damotte, D., Bouhnik, Y., Colombel, J., Delchier, J., Allez, M., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.069 · Cited by 382
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
Rana, A. K., Li, Y., Dang, Q., & Yang, F. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.10.016 · Cited by 303
The spectrum of celiac disease: epidemiology, clinical aspects and treatment
Tack, G. J., Verbeek, W. H. M., Schreurs, M. W. J., & Mulder, C. J. J. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.23 · Cited by 291
Targeting signal transduction as a strategy to treat inflammatory diseases
O'Neill, L. A. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2070 · Cited by 283
Etiology and Pathogenesis of Rheumatoid Arthritis
Firestein, G. S. (2017) · Kelley and Firestein's Textbook of Rheumatology · doi:10.1016/b978-0-323-31696-5.00069-3 · Cited by 278
New Clues in Celiac Disease Epidemiology, Pathogenesis, Clinical Manifestations, and Treatment
Lionetti, E., & Catassi, C. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2011.602443 · Cited by 260
Malamut, G., El Machhour, R., Montcuquet, N., Martin-Lannerée, S., Dusanter-Fourt, I., Verkarre, V., Mention, J.-J., Rahmi, G., Kiyono, H., Butz, E. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41344 · Cited by 256
Mechanisms and control of pathologic bone loss in periodontitis
Bartold, P. M., Cantley, M. D., & Haynes, D. R. (2010) · Periodontology 2000 · doi:10.1111/j.1600-0757.2010.00347.x · Cited by 254
Targeting Memory T Cells in Type 1 Diabetes
Ehlers, M. R., & Rigby, M. R. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0659-5 · Cited by 40
Metadata
- Authors
- Baslund, B., Tvede, N., Danneskiold‐Samsoe, B., Larsson, P., Panayi, G., Petersen, J., Petersen, L. J., Beurskens, F. J. M., Schuurman, J., van de Winkel, J. G. J., Parren, P. W. H. I., Gracie, J. A., Jongbloed, S., Liew, F. Y., & McInnes, I. B.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-09
- Volume
- 52
- Issue
- 9
- Pages
- 2686-2692
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1999709426
- Cited by
- 265
- References
- 32
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.